Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Utilities Select Sector SPDR Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $520 (market cap $134.06B), while Utilities Select Sector SPDR Fund trades at $43.06. The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| VRTX | XLU | |
|---|---|---|
Market Cap | $134.06B | — |
Sector | Health | — |
52-Week High | $557.96 | $47.73 |
52-Week Low | $376.62 | $41.86 |
Enterprise Value | $128.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
XLU trades at $43.45, up 0.86% with a bullish technical signal despite bearish moving averages. The utilities ETF shows neutral oscillators with RSI at 57.53, trading near key support at $43. Recent news highlights XLU's defensive positioning amid market volatility and AI power demand growth, though some analysts question its AI exposure concentration.
Outlook remains cautiously optimistic as utilities benefit from AI-driven power demand and defensive characteristics during economic uncertainty. Key risks include regulatory changes affecting data-center growth and interest rate sensitivity. The sector's stable dividend profile provides income support while growth potential depends on AI infrastructure expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
